Industry Trend

Site Sections

Menu








© 2023. All Rights reserved.

Overview for BRISTOL-MYERS SQUIBB

All Data per March 3, 2023

Industry:

Drug Manufacturers—General

Last Close:

69.30 USD

Expected Dividend:

3.10 %

Payoffs per Year:

4.0
Business Summary
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. The company offers products in hematology, oncology, cardiovascular, and immunology therapeutic classes. Its products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Opdivo for anti-cancer indications; Eliquis, an oral inhibitor indicated for the reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; and Orencia for adult patients with active RA and psoriatic arthritis, as well as reducing signs and symptoms in pediatric patients with active polyarticular juvenile idiopathic arthritis. The company also provides Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Abraxane, a solvent-free protein-bound chemotherapy product; mpliciti for the treatment of multiple myeloma; and Reblozyl for the treatment of anemia in adult patients with beta thalassemia. In addition, it offers Onureg for the continued treatment of adult patients with AML; Zeposia to treat relapsing forms of multiple sclerosis; Vidaza for the treatment of myelodysplastic syndrome subtypes; Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B; and Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for the treatment of adult patients with relapsed or refractory large B-cell lymphoma. The company sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. It has collaboration agreements with Pfizer, Inc.; Otsuka Pharmaceutical Co., Ltd.; Ono Pharmaceutical Co., Ltd.; Nektar Therapeutics; AVEO Pharmaceuticals, Inc.; Huyabio; and DarwinHealth, Inc. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.

Competitors View

Ordering

ABBVIE

USA		 1.03 4.28%
3.61%		 7.39% 5.46% 1.0 4.36
-9.47%		 43.02 13.08% 10.52 1.0

CHUGAI PHARMACEUTICAL

JPN		 0.96 2.56%
0.0%		 22.5% 6.68% 1.0 4.24
-32.13%		 32.9 15.38% 77.21 2.0

PFIZER

USA		 0.95 3.64%
3.96%		 2.76% 3.76% 1.0 3.02
-11.11%		 49.05 9.25% 42.54 3.0

ASTRAZENECA

GBR		 1.04 4.07%
2.74%		 1.15% 3.92% 1.0 11.56
-3.86%		 98.3 11.66% 37.27 4.0

DAIICHI SANKYO

JPN		 1.05 4.24%
0.0%		 0.0% 3.88% 1.0 8.15
-17.26%		 35.15 18.52% 61.0 5.0

SANOFI

FRA		 1.01 3.78%
4.03%		 0.74% 3.58% 1.0 0.57
-12.18%		 51.83 7.75% 57.12 6.0

BRISTOL-MYERS SQUIBB

USA
 0.98 2.8%
3.1%		 1.83% 2.78% 1.0 0.5
-24.44%		 34.92 17.8% 32.88 7.0

MERCK & CO.

USA		 1.12 3.12%
2.64%		 2.24% 3.15% 1.0 2.31
-11.68%		 55.47 10.37% 36.13 8.0

KYOWA HAKKO KOGYO

JPN		 0.96 1.88%
1.67%		 7.74% 2.44% 1.0 3.6
-15.61%		 35.6 3.07% 79.96 9.0

GILEAD SCIENCES

USA		 1.16 2.74%
3.6%		 5.91% 3.26% 1.0 0.15
-42.43%		 33.49 -1.11% 31.01 10.0

ELI LILLY AND COMPANY

USA		 1.04 2.43%
1.22%		 2.86% 2.52% 1.0 7.52
-12.71%		 42.91 5.87% 18.4 11.0

ROCHE

CHE		 0.92 3.28%
3.51%		 0.79% 3.11% 1.0 1.4
-15.85%		 37.23 2.14% 26.53 12.0

AMGEN

USA		 1.0 2.42%
3.28%		 8.46% 3.24% 1.0 3.5
-9.93%		 35.72 -5.0% 10.95 13.0

GLAXOSMITHKLINE

GBR		 0.96 5.37%
5.27%		 0.35% 5.0% -0.5 0.21
-24.56%		 49.96 2.63% 19.03 14.0

ASTELLAS PHARMA

JPN		 0.96 2.43%
0.0%		 1.74% 2.4% 1.0 1.09
-19.06%		 27.18 -1.76% 60.96 15.0

OTSUKA HOLDINGS CO., LTD.

JPN		 0.93 2.21%
2.54%		 0.0% 2.02% 1.0 -0.41
-14.62%		 28.52 12.2% 71.29 16.0

BAYER

GER		 1.02 2.51%
3.99%		 4.7% 2.83% 0.5 -0.36
-58.76%		 36.97 -17.89% 27.46 17.0

JOHNSON & JOHNSON

USA		 0.98 2.68%
0.0%		 0.0% 2.46% 1.0 -1.0
13.03%		 44.08 2.58% 40.67 18.0

GRIFOLS SA

ESP		 0.98 1.5%
nan%		 4.84% 1.7% -0.5 0.24
-46.29%		 31.86 -1.95% 31.7 nan

Information for BRISTOL-MYERS SQUIBB

Yield Triangle

Dividend & Close

Close Dividend Return (%)
Year
2012 32.59 1.36 4.17
2013 53.15 1.76 3.31
2014 59.03 1.45 2.46
2015 68.79 1.49 2.17
2016 58.44 1.14 1.95
2017 61.28 1.56 2.55
2018 51.98 1.60 3.08
2019 64.19 1.64 2.55
2020 62.03 2.29 3.69
2021 62.35 1.47 2.36
2023 69.30 2.15 3.10

Fundamentals

Chart